Expression of microRNA-370 in human breast cancer compare with normal samples


1 Department of Immunology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

2 Department of Immunology, Faculty of Medicine; Applied Physiology Research Centre, Isfahan University of Medical Sciences, Isfahan, Iran

3 Genetics and Molecular Biology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran


Background: Breast cancer is the second leading cause of deaths from cancer in the woman. MicroRNAs (miRNAs) are endogenous noncoding RNAs that are known critical player in carcinogenesis. The role of miR-370 in malignancies remains controversial because of its levels varying in different cancers according to its targets while the role of miR-370 in breast cancer has not been addressed so far. The aim of this study was to identify the expression pattern of miR-370 in human breast cancer tissue compared to adjacent healthy tissue.
Materials and Methods: Twenty-two fresh frozen tissues (normal and malignant) from patients with breast cancer were examined for miR-370 by quantitative real-time polymerase chain reaction method at 2013.
Results: We observed up-regulation (six-fold higher) of miR-370 in breast cancer tissue compared with normal adjacent tissue. Tumor samples in stage III, invasive ductal type, larger tumor size, human epidermal growth-factor receptor 2+, estrogen receptor/progesterone receptor−, P53 − status showed significantly increased expression in miR-370.
Conclusion: Together, miR-370 may acts as an onco-miRNA, and it may have a novel role in breast cancer. Detection of miR-370 and its targets could be helpful as a diagnostic biomarker and therapeutic target.


Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.  Back to cited text no. 1
Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.  Back to cited text no. 2
Kumar V, Abbas AK, Aster JC, Artist A, Perkins J. Robbins Basic Pathology. 9th ed. Philadelphia: Elsevier/Saunders; 2013. p. 511-24.  Back to cited text no. 3
Noroozi A, Jomand T, Tahmasebi R. Determinants of breast self-examination performance among Iranian women: An application of the health belief model. J Cancer Educ 2011;26:365-74.  Back to cited text no. 4
Turnpenny PD, Ellard S. Emery's Elements of Medical Genetics. 14th edition.UK: Elsevier Publishers; 2011. p. 192-219.  Back to cited text no. 5
Sassen S, Miska EA, Caldas C. MicroRNA: Implications for cancer. Virchows Arch 2008;452:1-10.  Back to cited text no. 6
Stefani G, Slack FJ. Small non-coding RNAs in animal development. Nat Rev Mol Cell Biol 2008;9:219-30.  Back to cited text no. 7
Garzon R, Calin GA, Croce CM. MicroRNAs in Cancer. Annu Rev Med 2009;60:167-79.  Back to cited text no. 8
Hammond SM. MicroRNAs as oncogenes. Curr Opin Genet Dev 2006;16:4-9.  Back to cited text no. 9
Kent OA, Mendell JT. A small piece in the cancer puzzle: MicroRNAs as tumor suppressors and oncogenes. Oncogene 2006;25:6188-96.  Back to cited text no. 10
Shenouda SK, Alahari SK. MicroRNA function in cancer: Oncogene or a tumor suppressor? Cancer Metastasis Rev 2009;28:369-78.  Back to cited text no. 11
Wang B, Wang H, Yang Z. miR-122 inhibits cell proliferation and tumorigenesis of breast cancer by targeting IGF1R. PLoS One 2012;7:e47053.  Back to cited text no. 12
Wu ZS, Wu Q, Wang CQ, Wang XN, Huang J, Zhao JJ, et al. miR-340 inhibition of breast cancer cell migration and invasion through targeting of oncoprotein c-Met. Cancer 2011;117:2842-52.  Back to cited text no. 13
Blenkiron C, Goldstein LD, Thorne NP, Spiteri I, Chin SF, Dunning MJ, et al. MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol 2007;8:R214.  Back to cited text no. 14
Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005;65:7065-70.  Back to cited text no. 15
Lowery AJ, Miller N, Devaney A, McNeill RE, Davoren PA, Lemetre C, et al. MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer. Breast Cancer Res 2009;11:R27.  Back to cited text no. 16
Yan LX, Huang XF, Shao Q, Huang MY, Deng L, Wu QL, et al. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA 2008;14:2348-60.  Back to cited text no. 17
Bandrés E, Cubedo E, Agirre X, Malumbres R, Zárate R, Ramirez N, et al. Identification by Real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues. Mol Cancer 2006;5:29.  Back to cited text no. 18
Chang KW, Chu TH, Gong NR, Chiang WF, Yang CC, Liu CJ, et al. miR-370 modulates insulin receptor substrate-1 expression and inhibits the tumor phenotypes of oral carcinoma. Oral Dis 2013;19:611-9.  Back to cited text no. 19
An F, Yamanaka S, Allen S, Roberts LR, Gores GJ, Pawlik TM, et al. Silencing of miR-370 in human cholangiocarcinoma by allelic loss and interleukin-6 induced maternal to paternal epigenotype switch. PLoS One 2012;7:e45606.  Back to cited text no. 20
Meng F, Wehbe-Janek H, Henson R, Smith H, Patel T. Epigenetic regulation of microRNA-370 by interleukin-6 in malignant human cholangiocytes. Oncogene 2008;27:378-86.  Back to cited text no. 21
Lo SS, Hung PS, Chen JH, Tu HF, Fang WL, Chen CY, et al. Overexpression of miR-370 and downregulation of its novel target TGFß-RII contribute to the progression of gastric carcinoma. Oncogene 2012;31:226-37.  Back to cited text no. 22
Wu Z, Sun H, Zeng W, He J, Mao X. Upregulation of microRNA-370 induces proliferation in human prostate cancer cells by downregulating the transcription factor FOXO1. PLoS One 2012;7:e45825.  Back to cited text no. 23
García-Ortí L, Cristóbal I, Cirauqui C, Guruceaga E, Marcotegui N, Calasanz MJ, et al. Integration of SNP and mRNA arrays with microRNA profiling reveals that miR-370 is upregulated and targets NF1 in acute myeloid leukemia. PLoS One 2012;7:e47717.  Back to cited text no. 24
Lardizábal MN, Nocito AL, Daniele SM, Ornella LA, Palatnik JF, Veggi LM. Reference genes for real-time PCR quantification of microRNAs and messenger RNAs in rat models of hepatotoxicity. PLoS One 2012;7:e36323.  Back to cited text no. 25
Mraz M, Pospisilova S. MicroRNAs in chronic lymphocytic leukemia: From causality to associations and back. Expert Rev Hematol 2012;5:579-81.  Back to cited text no. 26
He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S, et al. A microRNA polycistron as a potential human oncogene. Nature 2005;435:828-33.  Back to cited text no. 27
Mraz M, Pospisilova S, Malinova K, Slapak I, Mayer J. MicroRNAs in chronic lymphocytic leukemia pathogenesis and disease subtypes. Leuk Lymphoma 2009;50:506-9.  Back to cited text no. 28
Movahedi M, Haghighat S, Khayamzadeh M, Moradi A, Ghanbari-Motlagh A, Mirzaei H, et al. Survival rate of breast cancer based on geographical variation in iran, a national study. Iran Red Crescent Med J 2012;14:798-804.  Back to cited text no. 29
Fan L, Strasser-Weippl K, Li JJ, St Louis J, Finkelstein DM, Yu KD, et al. Breast cancer in China. Lancet Oncol 2014;15:e279-89.  Back to cited text no. 30
Cao X, Liu D, Yan X, Zhang Y, Yuan L, Zhang T, et al. Stat3 inhibits WTX expression through up-regulation of microRNA-370 in Wilms tumor. FEBS Lett 2013;587:639-44.  Back to cited text no. 31
Xu WP, Yi M, Li QQ, Zhou WP, Cong WM, Yang Y, et al. Perturbation of MicroRNA-370/Lin-28 homolog A/nuclear factor kappa B regulatory circuit contributes to the development of hepatocellular carcinoma. Hepatology 2013;58:1977-91.  Back to cited text no. 32
Gaur A, Jewell DA, Liang Y, Ridzon D, Moore JH, Chen C, et al. Characterization of microRNA expression levels and their biological correlates in human cancer cell lines. Cancer Res 2007;67:2456-68.  Back to cited text no. 33
Zhang X, Zeng J, Zhou M, Li B, Zhang Y, Huang T, et al. The tumor suppressive role of miRNA-370 by targeting FoxM1 in acute myeloid leukemia. Mol Cancer 2012;11:56.  Back to cited text no. 34
D'Ippolito E, Iorio MV. MicroRNAs and triple negative breast cancer. Int J Mol Sci 2013;14:22202-20.  Back to cited text no. 35
Thompson A, Brennan K, Cox A, Gee J, Harcourt D, Harris A, et al. Evaluation of the current knowledge limitations in breast cancer research: A gap analysis. Breast Cancer Res 2008;10:R26.  Back to cited text no. 36
Mattie MD, Benz CC, Bowers J, Sensinger K, Wong L, Scott GK, et al. Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol Cancer 2006;5:24.  Back to cited text no. 37
Heneghan HM, Miller N, Lowery AJ, Sweeney KJ, Kerin MJ. MicroRNAs as Novel Biomarkers for Breast Cancer. J Oncol 2009;2009:950201.  Back to cited text no. 38